Table 1.
Baseline characteristics
| Characteristic | Total (n = 855)* | ATO group (n = 382) | Non-ATO group (n = 373) |
| Median age, y (range) | 40 (18-65) | 39 (18-64) | 39 (18-65) |
| Sex, no. (%) | |||
| Male | 448 (52.4) | 196 (51.3) | 194 (52.0) |
| Female | 407 (47.6) | 186 (48.7) | 179 (48.0) |
| WBC, × 109/L (range) | 3.12 (0.20–165.97) | 2.81 (0.20–134.23) | 3.40 (0.36–161.70) |
| WBC, × 109/L, no. (%) | |||
| 0–9.9 | 588 (68.8) | 262 (68.6) | 258 (69.2) |
| 10–49.9 | 201 (23.5) | 90 (23.6) | 88 (23.6) |
| 50–99.9 | 52 (6.1) | 25 (6.5) | 23 (6.2) |
| ≥ 100 | 14 (1.6) | 5 (1.3) | 4 (1.1) |
| Hemoglobin, g/L (range) | 85 (27-167) | 84 (27-159) | 88 (36-149) |
| Platelet count, × 109/L (range) | 27 (2-194) | 27 (2-187) | 30 (2-194) |
| Sanz risk, no. (%) | |||
| Low | 191 (22.3) | 91 (23.8) | 85 (22.8) |
| Intermediate | 397 (46.4) | 171 (44.8) | 173 (46.4) |
| High | 267 (31.2) | 120 (31.4) | 115 (30.8) |
| ECOG score, no. (%) | |||
| 0–2 | 721 (84.3) | 335 (87.7) | 317 (85.0) |
| 3–4 | 134 (15.7) | 47 (12.3) | 56 (15.0) |
| Blasts in bone marrow, no. (%) | 85 (21-98) | 85 (24-98) | 85 (21-97) |
*
A total of 855 APL patients were enrolled in the trial. After achieving complete remission, 382 and 373 patients were randomly assigned to ATO and non-ATO group, respectively.